PIK3CA and neoplasm: When we included patients with low tumour expression of PTEN, there was no difference in pCR rates in patients whose tumours had a PIK3CA/ERBB family mutation and/or low PTEN expression (i.e., PI3K activated) compared with patients with WT tumours in either the TCH or the TCHL arm (Fig. 4d and e).